What Neuraptive Therapeutics does

Neuraptive Therapeutics is a clinical-stage biotechnology company developing NTX-001, a surgical treatment kit designed to repair severed peripheral nerves. The product is built on PEG-FUSION technology — the application of polyethylene glycol (PEG) via sequenced reagents to a nerve coaptation (neurorrhaphy) to fuse proximal and distal axonal membranes and prevent Wallerian degeneration. NTX-001 is positioned as an adjunct to standard suture neurorrhaphy and integrates three components: the PEG-FUSION chemistry, a proprietary drug delivery device for topical administration of active agents onto the nerve, and nerve-specific microsurgical instruments. The company is pursuing the FDA 505(b)(2) regulatory pathway using previously approved pharmaceutical ingredients presented in sterile solutions.

The company was founded in 2016 and is headquartered in Chesterbrook, Pennsylvania. Its core intellectual property is in-licensed from the University of Texas at Austin, with patent protection extending through 2038, supplemented by Neuraptive's own patent applications on the delivery device, formulation, and kit design. Neuraptive has secured three FDA designations for NTX-001: Fast Track Designation (May 2020), Orphan Drug Designation (January 2024), and Breakthrough Therapy Designation (September 2024). Two Phase 2 multi-center trials have been completed and Phase 3 enrollment began in October 2025 for upper extremity transected nerves, with a parallel Phase 2 program ongoing for prevention of postoperative facial paralysis.

The company is pre-revenue with no products approved or on market. Its target end users are surgeons and physicians specializing in peripheral nerve repair — including trauma, reconstructive, and facial nerve surgeons — operating in hospitals and surgical centers. The intended go-to-market is direct enterprise field sales to these institutions upon regulatory approval, leveraging the well-established reimbursement infrastructure for nerve repair procedures. Total disclosed funding is approximately $20 million across seed (2017), Series A led by New Rhein Healthcare Investors (2018), and a Ben Franklin Technology Partners financing (2022).

Name

Neuraptive Therapeutics

Legal name

Neuraptive Therapeutics, Inc.

Website

https://neuraptive.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Neuraptive Therapeutics is a clinical-stage biotechnology company developing NTX-001, a PEG-FUSION-based surgical kit for repairing peripheral nerve injuries, targeting hospitals and surgeons with FDA Fast Track, Orphan Drug, and Breakthrough Therapy Designations.

Ownership category

akta.pro rank

Product category

Peripheral Nerve Repair Therapeutics

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neural & Spinal Cord Regeneration (HLAAAGAI)

Keywords

• Peripheral nerve repair
• Nerve fusion therapeutics
• Biopharmaceutical development
• Surgical medical devices
• Clinical stage biotechnology

Headquarters

HQ city

Lafayette

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. NTX-001 Product Sales: Pre-commercial biotech company developing NTX-001, a surgical treatment kit for peripheral nerve repair. Revenue will come from product sales to hospitals and surgical centers upon regulatory approval. The company has two Phase 2 multi-center clinical trials completed and is enrolling in Phase 3 clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Neuraptive Therapeutics develops NTX-001, a surgical treatment kit for repairing severed peripheral nerves. NTX-001 integrates three components: (1) PEG-FUSION technology using polyethylene glycol to fuse axonal membranes of severed nerve stumps, (2) a specialized drug delivery device for topical administration of active agents on the nerve, and (3) nerve-specific microsurgical instruments. The product is being advanced through Phase 3 clinical trials under the 505(b)(2) regulatory pathway.

Product overview

Neuraptive Therapeutics is a biotechnology company developing the NTX-001 surgical treatment kit for peripheral nerve injuries. NTX-001 is a unified product comprising three integrated components: (1) PEG-FUSION nerve fusion technology using polyethylene glycol to fuse severed nerve endings, (2) a specialized drug delivery device for topical administration of active agents on nerves, and (3) proprietary microsurgical instruments designed for nerve repair procedures. The company also holds patent protection through 2038 for the NTX-001 technology licensed from the University of Texas at Austin.

Differentiator

Problem solved

Functional benefit

Products and services

• NTX-001 A surgical treatment kit for repairing severed peripheral nerves after trauma or peripheral nerve reconstruction procedures. Combines PEG-FUSION nerve fusion technology (using polyethylene glycol-based sequenced reagents applied to freshly coapted nerve endings to fuse axonal membranes and prevent Wallerian degeneration) with a specialized drug delivery device for topical administration of active agents and proprietary microsurgical instruments. Developed under the FDA 505(b)(2) pathway using previously approved pharmaceutical ingredients presented in sterile solutions. Intended for use by surgeons at hospitals and surgical centers performing peripheral nerve repair procedures.

Quantifiable outcome

• PEG-FUSION in combination with standard neurorrhaphy is superior in improving functional outcomes following peripheral nerve injury compared to standard neurorrhaphy alone

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• University of Texas at AustincoreTechnology or IntegrationNeuraptive has in-licensed technology from the University of Texas at Austin protecting a novel fusion system for repairing severed peripheral nerves. The in-licensed and issued patent estate protects the method of repairing nerves embodied in NTX-001. Patent protections expected to extend through 2038.

Scale indicators7 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Axogen: Axogen is the dominant commercial player in peripheral nerve repair with products including Avance nerve graft, Axoguard nerve cap, and Acroval connectors. It is the most directly comparable competitor to Neuraptive, addressing the same surgical specialty and patient population (peripheral nerve injuries) but with a tissue-based graft and connector portfolio rather than a chemical fusion approach.
• Checkpoint Surgical: Checkpoint Surgical develops nerve stimulation and monitoring devices used during surgery, including the Checkpoint Stimulator/Locator for intra-operative nerve identification. While its focus is on nerve preservation and stimulation rather than repair, it serves the same surgical specialties and addresses complementary unmet needs in peripheral nerve surgery.
• Polyganics: Polyganics is a Netherlands-based medical device company developing bioresorbable nerve repair devices such as the Neurolac nerve guide for peripheral nerve injuries. It competes directly with Neuraptive in the surgical peripheral nerve repair market, with a complementary product approach (synthetic conduits vs. PEG fusion).

Broad incumbents

• Integra LifeSciences: Integra LifeSciences is a large diversified medical device company with a peripheral nerve repair portfolio (e.g., NeuraGen nerve guide, NeuraWrap) and broader regenerative tissue technologies. It serves the same surgeon customers and patient population as Neuraptive but as part of a much larger portfolio spanning neurosurgery, ENT, and reconstructive surgery.
• Stryker: Stryker is a major diversified medical device and surgical equipment company with products used in trauma, orthopedic, and reconstructive surgical settings — including those where peripheral nerve repair procedures occur. While it does not have a dedicated nerve fusion product, its broad surgical footprint and hospital relationships make it a relevant incumbent peer and potential strategic acquirer.
• Medtronic: Medtronic is a global medical device leader with neuromodulation and neurosurgery franchises that overlap indirectly with peripheral nerve applications. It addresses related but distinct indications (spinal cord stimulation, deep brain stimulation) and could be a strategic partner or acquirer given the convergence of nerve repair and neuromodulation.
• Abbott Laboratories: Abbott is a large diversified medical device and diagnostics company with neuromodulation products and broad surgical/electromedical device portfolios. While not a direct competitor in peripheral nerve fusion, it operates in adjacent nerve stimulation and surgical device categories and could represent a strategic exit path for Neuraptive.
• Boston Scientific: Boston Scientific is a global medical device leader with significant neuromodulation, peripheral intervention, and pain management franchises. Although its nerve-related products focus on stimulation rather than surgical repair, it is a relevant incumbent with similar hospital channels and could be a strategic acquirer.

Emerging players

• Tissium: Tissium is a Paris-based medtech developing programmable biomaterials for tissue reconstruction, including nerve repair applications. It shares the philosophy of enabling natural tissue repair with Neuraptive's PEG-FUSION approach and is an emerging competitor in the same surgical specialty space.
• Cohera Medical: Cohera Medical develops surgical adhesives and sealants used in tissue repair procedures. While its products are not specifically indicated for peripheral nerve repair, its chemical adhesion technology is philosophically adjacent to PEG-FUSION and represents a comparable emerging tissue repair platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Neuraptive
• Facebookfacebook.com/Neuraptive-Therapeutics-Inc-113166970441474
• LinkedInlinkedin.com/company/neuraptive-therapeutics/about

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuraptive Therapeutics